TOVX

Theriva Biologics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$0.16

Price (1 Year)

$0.39 $0.16

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %25.2 / %30
Non-compliant assets / Total market cap %0 / %30
Non-compliant revenue / Total income %34.9 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.

Website

Analysis (Turkish): TOVX Hissesi Caiz mi, Helal mi? Theriva Biologics, Inc. Katılım Analizi